Abstract: Objective  To investigate the effect of Spironolactone on the level of serum chemerin and cardiac function in patients with acute myocardial infarction（AMI）. Methods   A total of 96 patients with AMI were selected and divided into two groups according to different treatment methods. The control group was treated with conventional treatment and the study group was given Spironolactone. The differences and changes in serum chemerin levels before and after treatment were observed and compared between two groups. The relevant indexes of cardiac function before and after 6 months of treatment were compared between two groups: left ventricular end diastolic diameter (LVEDD),  left ventricular ejection fraction (LVEF) and left ventricular end systolic diameter (LVESD) levels. The adverse reactions of two groups were observed. Results  The serum chemerin levels at 3 months and 6 months after treatment were significantly lower than those before treatment (P<0.05). The serum chemerin level in study group at 3 and 6 months after treatment was significantly lower than that in control group(P<0.05). At 6 months after treatment,  the levels of LVEF,  LVEDD and LVESD were significantly improved compared to before treatment(P<0.05). At 6 months after treatment,  the LVFE level in study group was significantly higher than that in control group (P<0.05). The LVEDD level and the LVESD level at 6 months after treatment were significantly lower than those in control group(P<0.05). Conclusion  Spironolactone treatment in patients with AMI can significantly reduce the serum chemerin level and improve the level of relevant indicators of cardiac function in patients with high safety.

Key words:  myocardial infarction, spironolactone, chemotactic factors